Creative Planning Has $910,000 Position in Biohaven Ltd. (NYSE:BHVN)

Creative Planning boosted its stake in shares of Biohaven Ltd. (NYSE:BHVN) by 57.9% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 18,209 shares of the company’s stock after buying an additional 6,674 shares during the quarter. Creative Planning’s holdings in Biohaven were worth $910,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Redwood Wealth Management Group LLC acquired a new position in Biohaven during the 2nd quarter worth about $61,000. Elkhorn Partners Limited Partnership acquired a new position in Biohaven during the 2nd quarter worth about $125,000. Cypress Wealth Services LLC bought a new position in shares of Biohaven in the 3rd quarter worth about $224,000. Diversified Trust Co bought a new position in shares of Biohaven in the 3rd quarter worth about $239,000. Finally, Quarry LP raised its position in shares of Biohaven by 614.3% in the 2nd quarter. Quarry LP now owns 5,000 shares of the company’s stock worth $174,000 after acquiring an additional 4,300 shares in the last quarter. 88.78% of the stock is owned by institutional investors and hedge funds.

Biohaven Trading Up 2.2 %

Biohaven stock opened at $50.86 on Friday. Biohaven Ltd. has a 1-year low of $26.80 and a 1-year high of $62.21. The firm has a market capitalization of $4.81 billion, a price-to-earnings ratio of -5.56 and a beta of 1.31. The firm’s fifty day moving average price is $45.69 and its two-hundred day moving average price is $40.14.

Biohaven (NYSE:BHVN) last released its quarterly earnings data on Thursday, August 8th. The company reported ($3.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.72) by ($1.92). On average, research analysts forecast that Biohaven Ltd. will post -8.81 EPS for the current year.

Insider Buying and Selling at Biohaven

In other Biohaven news, Director John W. Childs acquired 21,052 shares of the company’s stock in a transaction on Wednesday, October 2nd. The shares were purchased at an average cost of $47.50 per share, with a total value of $999,970.00. Following the completion of the purchase, the director now owns 21,052 shares of the company’s stock, valued at approximately $999,970. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director John W. Childs purchased 21,052 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were bought at an average cost of $47.50 per share, with a total value of $999,970.00. Following the completion of the transaction, the director now directly owns 21,052 shares of the company’s stock, valued at approximately $999,970. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gregory Bailey purchased 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 24th. The shares were purchased at an average cost of $44.19 per share, for a total transaction of $220,950.00. Following the completion of the transaction, the director now directly owns 1,620,071 shares of the company’s stock, valued at $71,590,937.49. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 16.00% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on BHVN. Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a research report on Wednesday, October 23rd. Sanford C. Bernstein lifted their price objective on Biohaven from $55.00 to $66.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 24th. Bank of America lifted their price objective on Biohaven from $52.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. UBS Group lowered their price objective on Biohaven from $55.00 to $54.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. Finally, Jefferies Financial Group began coverage on Biohaven in a research report on Monday, September 16th. They issued a “buy” rating and a $57.00 price objective for the company. Thirteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $61.92.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.